# Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan

> **NCT00658879** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 251 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Somavert (Pegvisomant)

## Key facts

- **NCT ID:** NCT00658879
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-07
- **Primary completion:** 2016-11-09
- **Final completion:** 2016-11-09
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2023-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658879, "Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00658879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*